Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05672199 · ClinicalTrials.gov registry record · Phase 2
Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT05672199 is a Phase 2 study that was terminated before completion, run by Amgen. The registered enrollment target is 25 participants.
The verdict
NCT05672199, a Phase 2 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the long-term safety and tolerability of efavaleukin alfa in participants with moderate to severe ulcerative colitis (UC).
Interventions
- DRUG Placebo
- DRUG Efavaleukin alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-04-28 |
| Est. Completion | 2024-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05672199
The ClinicalTrials.gov registry entry for NCT05672199 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05672199 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05672199 about?
NCT05672199 is a clinical study titled "Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis". The primary objective of this study is to evaluate the long-term safety and tolerability of efavaleukin alfa in participants with moderate to severe ulcerative colitis (UC).
What is the current status of trial NCT05672199?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2023-04-28. Estimated completion is 2024-10-31.
What interventions are being tested in trial NCT05672199?
The interventions under investigation include: Placebo (DRUG), Efavaleukin alfa (DRUG).
Who is sponsoring clinical trial NCT05672199?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.